Ysios Capital is a leading European venture capital firm that specializes in investing in companies addressing high unmet medical needs. With a strong focus on the life sciences sector, Ysios Capital aims to transform capital into medical breakthroughs that have a positive impact on patients and society. Driven by science, Ysios Capital's international team seeks out exceptional biotech ventures with pioneering science and a drive to change patients' lives.

They invest in companies that bring life-changing treatments to patients, particularly in areas with high unmet need. Since its establishment in 2008, Ysios Capital has grown rapidly and is now the largest life sciences venture capital firm in Spain, managing over €400 million in assets across three global funds. Their investment successes have significantly contributed to the growth of Spain's biotech sector.

Committed to responsible investment, Ysios Capital integrates environmental, social, and governance (ESG) principles and best practices throughout their activities. To date, Ysios Capital's portfolio includes several innovative companies developing novel therapeutics for various diseases, such as cancer, inflammatory bowel disease, hypertension, and blinding inherited retinal diseases